ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

NCT01730612 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

HER2 Negative Breast Carcinoma Expressing CEA

Interventions

DRUG: TF2 - 68 Ga-IMP-288:

Sponsor

Nantes University Hospital

Collaborators

[object Object]
[object Object]